Listen: VC malaise, FDA confusion, & yet another Alzheimer’s debate

Is the era of the unicorn over? What’s gotten into the FDA? And will a NASH drug ever work?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. We also discuss an FDA plot twist for a novel ALS treatment, a second shot for a once-promising liver drug, and the latest in the Covid-19 pandemic.

For more on what we cover, here’s the news on biotech VCs; here’s the story on Intercept Pharmaceuticals; here’s more on Amylyx Pharmaceuticals; here’s the latest on Paxlovid prescribing; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].